RadNet, Inc. (RDNT) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures.
Is RadNet, Inc. stock overvalued or undervalued in 2026?
As of October 3, 2026, RadNet, Inc. (RDNT) trades at $69.93 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: RadNet, Inc.
Market cap $5B · 52 weeks $52 – $84 (16 % below the high) · P/E no earnings · 2027 expected P/E 78.9× · Dividend none · Next earnings November 9, 2026 · expected EPS $0.21 · Price as of Oct 3 · accounts published Aug 9.
- Valuation: EV/EBITDA 20.8× (no earnings).
- Business: ROIC 1 % (weak).
- Balance sheet: Net debt/EBITDA 4.3× (fragile).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 0 of 4 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 4.5 %, fails.
- ROIC 1.4 %, fails.
- Net debt / EBITDA 4.3×, fails.
Against its peers (reference peers) — RadNet, Inc.: P/E —; EV/EBITDA 20.8×; ROIC 1.4 %; $5.5B. Sotera Health Company (P/E 32.4×; EV/EBITDA 13.3×; ROIC 8.8 %; $5.3B), Merit Medical Systems, Inc. (P/E 40.6×; EV/EBITDA 17.1×; ROIC 5.6 %; $5.1B), Bausch + Lomb Corporation (P/E —; EV/EBITDA 14.7×; ROIC 3.2 %; $6.1B).
Profitability
| Return on Equity | -1.95% |
| Return on Invested Capital | 1.38% |
| Return on Assets | -0.50% |
| Gross Margin | 9.70% |
| Operating Margin | 4.00% |
| Net Margin | -0.93% |
Financial Health
| Debt / Equity | 1.99 |
| Current Ratio | 1.48 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.07 |
Price Performance
| 1 month | -4.26% |
| 3 months | +7.59% |
| Year-to-date | -1.09% |
| 1 year | -9.86% |
| 3 years | +137.77% |
| 5 years | +144.53% |
Related companies: BLCO · BRKR · BTSG · CHE · IRTC · KRYS · MMSI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of RDNT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks